

# Quantitative Analysis of AKT/mTOR Pathway using Immunoprecipitation and Targeted Mass Spectrometry

Bhavin Patel, Suzanne Smith, Alex Behling, Kaitlyn Conner, Ryan Bomgarden, Kay Opperman, Barbara Kaboord, John Rogers  
Thermo Fisher Scientific, Rockford, IL, USA

## Overview

**Purpose:** Identification and quantitation of multiple AKT/mTOR pathway proteins using an optimized immunoprecipitation to mass spectrometry (IP-MS) workflow in two human carcinoma cell lines.


**Methods:** Serum starved A549 and HCT116 cells were stimulated with EGF or IGF. Several AKT/mTOR pathway targets were enriched by improved IP using Protein A/G and Streptavidin magnetic beads and IP eluates were processed using in-solution digestion for LC-MS/MS analysis. A targeted SRM/MS assay was developed for quantitation of AKT/mTOR pathway target peptides (EGFR, IR, IGF1R, IRS1, AKT2, AKT1, PTEN, PIK3CA, PIK3R1, mTOR, GSK3b, PRAS40, TSC2 and p70S6K). Multiple targets were also immunoprecipitated simultaneously and quantitated by targeted SRM assay. Improved IP combined with targeted MS workflow was applied to assess recovery of recombinant proteins in a human plasma matrix.

**Results:** In previous work, we assessed over 13 different commonly used resins for IP and determined that magnetic particle supports had the lower background, higher recovery and better reproducibility compared to agarose, sepharose and ultralink supports. In this study, we validated numerous antibodies for IP-MS and optimized specific wash buffers for both Pierce Protein A/G and Streptavidin magnetic beads. Enrichment of total and phosphorylated forms of EGFR, AKT isoforms, PI3K and PTEN resulted in quantitation of low to sub nanogram target levels in two cell lysates by LC-SRM/MS. In addition, we used IP-MS to enrich and quantify recombinant EGFR, AKT2/AKT1, PTEN and PI3K spiked into a human plasma matrix and were able to quantify targets as low as 10ng/ml. As our improved IP-MS workflow results in higher yield of target protein and less non-specific binding, we were able to combine multiple target antibodies to enrich multiple AKT/mTOR pathway protein targets for a single IP-MS analysis. This multiplex targeted assay can be used for simultaneous detection and quantitation of AKT/mTOR pathway proteins in other cancer cell lines or tissue samples.

## Introduction

PI3K/AKT/mTOR pathway plays a central role in tumor progression and anti-cancer drug resistance. The quantitative measurement of protein expression and PTMs of the AKT/mTOR pathway is necessary for precisely characterizing the disease, monitoring cancer progression and determining treatment responses.<sup>1</sup> A major limitation in the quantitation of AKT/mTOR pathway proteins is the lack of rigorously validated methods/reagents and a reliance on semi-quantitative results from Western blotting. MS is increasingly becoming the detection methodology of choice for protein abundance and PTMs. IP is commonly used upstream of MS as an enrichment tool for low-abundant protein targets.<sup>2,3</sup> In addition to protein identification, IP can be combined with targeted MS to identify proteins of interest and protein-protein interactions.<sup>4</sup>

Figure 1. EGFR-PI3K-AKT-mTOR pathway.



## Methods

### Cell Culture

A549 and HCT116 cells were grown in F-12K (Hamm's) and McCoy's 5A Media, respectively, with 10% FBS/1xPenStrep to ~70% confluency. Cells were starved in 0.1% charcoal stripped FBS for 24 hours before stimulation with 100ng/ml of IGF or EGF for 15 minutes.

### Immunoprecipitation and MS Sample Preparation

The Thermo Scientific™ Pierce MS-Compatible Magnetic IP Kit (Protein A/G) was used to screen and validate antibodies for EGFR, total AKT, phospho AKT, PTEN, PIK3CA, IGF1R, IR, mTOR, GSK3b, TSC2, p70S6K, PRAS40 and IRS1 from 500µg cell lysate. Validated antibodies were biotinylated with the Thermo Scientific™ Pierce Antibody Biotinylation Kit for IP. The Thermo Scientific™ Pierce MS-Compatible Magnetic IP Kit (Streptavidin) was used to perform the single or multiplex IPs for target enrichment. IP samples were processed by an in-solution digestion method where IP eluates were reconstituted in 6M Urea, 50mM TEAB, pH 8.5 followed by reduction, alkylation and trypsin digestion overnight at 37°C. The digested samples were acidified with TFA before MS analysis.


Liquid Chromatography and Mass Spectrometry

Prior to MS analysis, tryptic digest samples were desalted on-line using the Thermo Scientific™ Acclaim™ PepMap 100 C18 Trap Column. For discovery MS, the samples were analyzed by nanoLC-MS/MS using a Thermo Scientific™ Dionex™ UltiMate™ 3000 RSLCnano System and Thermo Scientific™ Orbitrap Fusion™ Mass Spectrometer. For targeted MS, the samples were analyzed by nanoLC-SRM/MS with the UltiMate 3000 RSLCnano System and Thermo Scientific™ TSQ™ Vantage™ Mass Spectrometer.

MS Data Analysis

Discovery MS data were analyzed with Thermo Scientific™ Proteome Discoverer™ 1.4 and Scaffold 4.0 to assess percent sequence coverage, unique peptides, MS1 intensities, spectral counts and PTMs. The Proteome Discoverer software searches were executed using the Uniprot human protein database. The following search parameters were used: two missed cleavages permitted, carbamidomethylation on cysteine fixed modification, and oxidation (methionine), acetyl (N-terminus proteins) and phosphorylation (S, T, Y) variable modifications. The mass tolerances for precursor ions and fragment ions were 20 ppm and 0.6 Da, respectively. Tryptic peptides with highest MS1 intensity and relevant phosphorylation sites were selected from the discovery data for targeted assay development. For targeted LC-SRM/MS data analysis, Thermo Scientific™ Pinpoint software and Thermo Scientific™ Skyline software were used to measure limit of quantitation (LOQ) from the calibration curve and target analyte concentration from unknown samples.

Figure 2. Experimental workflow for IP-MS assay development.



Protein targets are immune-enriched from matrix and analyzed by silver stain or Western blot after gel electrophoresis. IP samples are also digested with trypsin and analyzed by nanoLC-MS/MS to identify candidate quantitative peptides. Heavy isotope-labeled, quantitative peptide standards are then used in targeted SRM or MRM assays for absolute quantitation.

Results



Figure 3. Enrichment of medium to low abundant AKT-mTOR pathway targets from A549 cells.

IP Antibody	Targets Identified	Neat No. of Unique Peptides	IP Enriched No. of Unique Peptides		Relevant Phosphopeptide Identified
			Unstimulated	+ IGF or EGF	
EGFR	EGFR	14	41	+IGF: 42 +EGF: 51	+IGF: Thr693, Ser991, Ser1166 +EGF: Ser991, Tyr1110, Tyr1172
Phospho AKT	AKT1	-	3	20	+IGF: Ser473
	AKT2	-	-	14	+IGF: Ser474
	AKT3	-	-	13	N/A
AKT1	AKT1	-	16	12	N/A
	AKT2	-	9	11	N/A
	AKT3	-	5	3	N/A
PTEN	PTEN	-	5	10	N/A
PIK3CA	PIK3CA	-	-	7	N/A
	PIK3R1	-	-	5	N/A
	PIK3R2	-	-	4	N/A
Phospho mTOR	mTOR	2	75	82	+IGF: Thr2446, Ser2448
	RICTOR	-	0	2	N/A
	SIN1	-	2	3	N/A
	Gbl	-	4	4	N/A

AKT-mTOR pathway targets were immunoprecipitated from unstimulated and IGF or EGF-stimulated A549 lysate with Thermo Scientific™ Pierce MS-Compatible Magnetic IP Kits (Protein A/G or Streptavidin) for MS analysis. Higher number of unique peptides were identified in IP enriched samples compared to neat lysate. Protein isoforms and interacting partners were identified for AKT, PIK3CA and mTOR targets. Relevant phosphorylation sites were detected for EGFR, AKT1, AKT2 and mTOR. Candidate quantitative peptides were selected for targeted MS assay development.

Figure 4. Identification of multiple phosphorylation sites for EGFR peptides in IGF or EGF-stimulated A549 cells.

A EGFR Protein Sequence



A) IP-MS of IGF or EGF stimulated A549 lysate allowed simultaneous analysis of multiple phosphorylation sites for EGFR. Identified peptides are highlighted in yellow and modified amino acids (S, T, Y) are in green. EGF-stimulation allowed detection of phosphorylation at Ser991, Tyr1110 and Tyr1172. Phosphorylation at Thr693, Ser991 and Ser1166 were identified with IGF stimulation. B) Representative MS/MS spectra of EGFR Thr693 phosphopeptide ELVEPL(p)PSGEAPNQALLR.

Immunoprecipitation to targeted MS application (nanoLC-SRM/MS)

Targeted SRM assay was developed and validated for absolute quantitation of EGFR, AKT1, AKT2, PTEN, PIK3CA and PIK3R1 targets.

Figure 5. Detection and quantitation limits of EGFR, AKT2, AKT1, PTEN, PIK3CA and PIK3R1 peptides.

Target	Peptide No.	LOD (fmol)	LLOQ (fmol)	ULOQ (fmol)	Linearity (R <sup>2</sup> )
EGFR	Total Peptide	0.2	3.9	1000	0.9977
	Phospho Peptide	0.2	3.9	1000	0.9997
AKT2	Peptide 1	0.2	3.9	1000	0.9998
	Peptide 2	3.9	15.6	1000	0.9599
AKT1	Peptide 1	0.2	3.9	1000	0.9541
	Peptide 2	0.2	3.9	1000	0.9999
PTEN	Peptide 1	0.2	3.9	1000	0.9997
	Peptide 2	0.2	3.9	1000	0.9999
PIK3R1	Peptide 1	0.2	3.9	1000	0.9997
	Peptide 2	0.2	3.9	1000	0.9999
PIK3CA	Peptide 1	0.2	3.9	1000	0.9981

All six targets were monitored with linear quantitation. Total EGFR, phospho EGFR, AKT2, PTEN, PIK3CA and PIK3R1 peptides were quantified from 3.9 fmol to 1000 fmol.

Figure 6. Multiplex immunoprecipitation to MS applications.

A Discovery MS (nanoLC-MS/MS)

IP Antibody	Targets Identified	No. of Unique Peptides	
		Unstimulated	+ EGF
Total EGFR	EGFR	41	51
AKT1	AKT1	9	8
	AKT2	-	4
	AKT3	-	5
PTEN	PTEN	2	6

B Targeted MS (nanoLC-SRM/MS)

IP Antibody	Quantotypic Peptide	Concentration (fmol)	
		Unstimulated	+ EGF
Total EGFR	Total EGFR	323.8	446.4
	Phospho EGFR	7.8	18.4
AKT1	AKT1	31.6	42.4
	AKT2	37	47.8
Total PTEN	PTEN	33.2	47.2

EGFR, AKT isoforms and PTEN were enriched simultaneously from unstimulated and EGF stimulated A549 lysates with biotinylated antibodies and Thermo Scientific™ Pierce MS-Compatible Magnetic IP Kit (Streptavidin). A) All five targets were identified by discovery MS. B) Total EGFR, phospho-EGFR, AKT1, AKT2 and PTEN peptides were quantified in low to sub-fmol concentrations by LC-SRM/MS. Phospho-EGFR peptide showed more than two fold increase in response to EGF stimulation.

**Figure 7. Recovery of recombinant rEGFR, rAKT1, rAKT2 and rPIK3R1 proteins from plasma matrix.**

IP Antibody	Matrix	No. of Unique Peptides	Quantified by LC-SRM/MS
EGFR	10ng rEGFR/500µg Plasma	13	9fmol/ 1.2ng
Pan AKT	10ng rAKT1/500µg Plasma	9	9fmol/ 0.5ng
	10ng rAKT2/ 500µg Plasma	4	9fmol/ 0.5ng
PIK3R1	10ng rPIK3R1/500µg Plasma	6	3fmol/ 0.25ng

rEGFR, rAKT1, rAKT2 and rPIK3R1 spiked into 0.5mg plasma were detected and quantitated in low fmol/nanogram concentrations.

**Figure 8. Summary of PI3K/AKT/mTOR pathway targets identified and quantified in two cell lines without and with enrichment.**

Target	Cell line	Detected by Orbitrap Fusion		Quantified by SRM	
		Neat	Enriched-IP	Neat	Enriched-IP
EGFR	A549	+ (14)*	+ (41)	-	+
	HCT116	+ (10)	+ (34)	-	+
AKT1	A549	-	+	-	+
	HCT116	-	+	-	+
AKT2	A549	-	+	-	+
	HCT116	-	+	-	+
AKT3	A549	-	+	N/A	N/A
	HCT116	-	+	N/A	N/A
PIK3CA	A549	-	+	-	+
	HCT116	-	+	-	+
PIK3R1	A549	-	+	-	+
	HCT116	-	+	-	+
PTEN	A549	-	+	-	+
	HCT116	-	+	-	+
mTOR	A549	+ (2)	+ (82)	N/A	N/A
	HCT116	+ (9)	+ (110)	N/A	N/A
IGF1R	A549	+ (4)	+ (22)	N/A	N/A
	HCT116	-	+	N/A	N/A
IRS1	A549	-	+	N/A	N/A
	HCT116	-	+	N/A	N/A

+ ≥2 unique peptides for discovery MS and >LLOQ for targeted MS  
\* No. of unique peptides

## Conclusion

- Immunoprecipitation using MS-Compatible Magnetic IP Kits (Protein A/G and Streptavidin) for MS applications resulted in a higher yield of AKT/mTOR pathway target proteins and less non-specific binding proteins.
- IP to MS analysis of EGFR, total AKT, phospho AKT, PIK3CA and phospho mTOR enabled identification of multiple isoforms, relevant protein interactions and phosphorylation sites.
- Multiplex IP to targeted MS allowed simultaneous quantitation of total EGFR, phospho EGFR, AKT2, AKT1 and PTEN target peptides in low to sub fmol range from unstimulated and stimulated A549 cell lysates.
- Enrichment of as low as 10ng recombinant EGFR, AKT2, AKT1 and PIK3R1 proteins spiked in plasma enabled absolute quantitation by targeted MS.
- Enrichment is necessary for identification and quantitation of low abundant signaling pathway proteins and PTMs for MS applications.
- Future work will focus on development of targeted MS assay for quantitation of additional AKT/mTOR pathway targets.

## References

- Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. *Genes Dev.* 2012 Apr 1; 26(7):641-50.
- Gingras AC, Gstaiger M, Raught B, Aebersold R. Analysis of protein complexes using mass spectrometry. *Nat Rev Mol Cell Biol.* 2007 Aug; 8(8):645-54.
- Carr SA, Abbatiello SE, Ackermann BL et al. Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach. *Mol Cell Proteomics.* 2014 Mar; 13(3):907-17.
- Ackermann BL. Understanding the role of immunoaffinity-based mass spectrometry methods for clinical applications. *Clin Chem.* 2012 Dec; 58(12):1620-2.

Research Use Only. Not for use in diagnostic procedures.

[www.thermoscientific.com](http://www.thermoscientific.com)

©2015 Thermo Fisher Scientific Inc. All rights reserved. ISO is a trademark of the International Standards Organization. All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries. This information is presented as an example of the capabilities of Thermo Fisher Scientific products. It is not intended to encourage use of these products in any manners that might infringe the intellectual property rights of others. Specifications, terms and pricing are subject to change. Not all products are available in all countries. Please consult your local sales representative for details.



**Africa** +43 1 333 50 34 0  
**Australia** +61 3 9757 4300  
**Austria** +43 810 282 206  
**Belgium** +32 53 73 42 41  
**Canada** +1 800 530 8447  
**China** 800 810 5118 (free call domestic)  
 400 650 5118

**Denmark** +45 70 23 62 60  
**Europe-Other** +43 1 333 50 34 0  
**Finland** +358 10 3292 200  
**France** +33 1 60 92 48 00  
**Germany** +49 6103 408 1014  
**India** +91 22 6742 9494  
**Italy** +39 02 950 591

**Japan** +81 45 453 9100  
**Korea** +82 2 3420 8600  
**Latin America** +1 561 688 8700  
**Middle East** +43 1 333 50 34 0  
**Netherlands** +31 76 579 55 55  
**New Zealand** +64 9 980 6700  
**Norway** +46 8 556 468 00

**Russia/CIS** +43 1 333 50 34 0  
**Singapore** +65 6289 1190  
**Spain** +34 914 845 965  
**Sweden** +46 8 556 468 00  
**Switzerland** +41 61 716 77 00  
**UK** +44 1442 233555  
**USA** +1 800 532 4752